TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05840913
Drug: Articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge
Normalized name: articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic injection for intra- operative pain control
Study: NCT05712681
Drug: JP-1366 20mg tablet
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: T : JP-1366 20mg tablet after the meal
Study: NCT05712681
Drug: JP-1366 20mg tablet
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: R : JP-1366 20mg tablet under fasting condition
Study: NCT06241846
Drug: YL201 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks on Day 1 or twice every 3 weeks on Day 1 and Day 8 during a 3-week (21-day) cycle.
Study: NCT05002309
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of antidepressants follows best-established evidence for treating depression in adolescents and young adults. We will offer treatment with fluoxetine, starting at 10mg a day, increasing to 20mg a day after 1 week if tolerated; a protocol established as safe and effective in adolescents and adults in multiple trials. Additional increases to 40 or 60mg will be possible based on positive effects and side-effects and clinical judgement, as recommended in this age group. In cases of intolerance or adverse reaction to fluoxetine, we will switch to sertraline (25-200mg) or escitalopram (5-20mg), two antidepressants licensed by the FDA for major depressive disorder in adolescents. Treatment will be optimized over 16 weeks, a time-frame comparable to the CBT arm. Pharmacotherapy will be managed and prescribed by qualified psychiatrists when starting treatment and reviewed after 1 week, 2 weeks and then in 2-weekly intervals for the remainder of the 16 weeks acute treatment period.
Study: NCT06161493
Drug: ZEN003694
Approvals — FDA: no, EMA: no, PMDA: no
Description: A bromodomain extra-terminal inhibitor (BETi) that blocks a group of proteins called bromodomain and extra-terminal (BET), which may counteract the effect of NSD3 on tumor growth.
Study: NCT05660538
Drug: Placebo (matched to VX-548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to VX-548 for oral administration.
Study: NCT05660538
Drug: Placebo (matched to pregabalin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to pregabalin for oral administration.
Study: NCT05110261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available 0.9% (w/v) saline (sterile for human use) fixed IM dose of 0.5 mL (if weight \<5 kg) or 1.0 mL (if weight \>=5 kg)
Study: NCT05759767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children in this group will receive placebo once daily for 3 weeks after ESWL session.
Study: NCT04759703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT06567392
Drug: [14C] HRS-5965
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive single dose of orally \[14C\] HRS-5965 on Day 1.
Study: NCT04558736
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously (IV)
Study: NCT05849207
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered at 50, 40, 32, or 25 mg/k/d intravenous infusion (IV) continuously for two days starting 60-72 hours after transplant.
Study: NCT05023018
Drug: NEO100
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEO100 is a purified form of perillyl alcohol.
Study: NCT06570200
Drug: PMPR+iPRF+Vit.D
Approvals — FDA: no, EMA: no, PMDA: no
Description: locally applied iPRF plus vitamin D in the periodontal pocket
Study: NCT04941885
Drug: Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant receives Inetetamab plus cyclophosphamide metronomic chemotherapy plus AI.
Study: NCT05113615
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo Respimat inhaler
Study: NCT04756531
Drug: PF-07321332 Dose 1
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07321332 Dose 1 or Placebo
Study: NCT06248710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo nose spray contains a saltwater solution and will be applied like the Syntocinon nose spray containing oxytocin.
Study: NCT03686657
Drug: Val, Cel and Met XR Low
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.
Study: NCT03686657
Drug: Val, Cel and Met XR High
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg metformin-HCL XR plus 200 mg celecoxib once-a-day in the morning and 320 mg valsartan once-a-day 6 hours later in the afternoon for 26 weeks.
Study: NCT04809805
Drug: BAY2666605
Approvals — FDA: no, EMA: no, PMDA: no
Description: One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.
Study: NCT05715762
Drug: NO inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO inhalation at 20 ppm
Study: NCT04514835
Drug: Cisplatin+Capecitabine+Sintilimab
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The first stage:concurrent chemoradiotherapy，cisplatin，25-30mg/m2 ivgtt d1;capecitabine,800mg/m2, bid d1-5，qw，5weeks;concurrent radiotherapy,1.8-2Gy/d，5d/W，50-50.4Gy.~second stage:Sintilimab, 200mg,q3w, a total of 3 times，Each infusion lasted for 30-60 min until disease progression or intolerable toxicity, with a maximum duration of no more than 12 months.
Study: NCT04744103
Drug: TCA
Normalized name: RTCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a TCA peel as a treatment for their actinic cheilitis.
Study: NCT00817609
Drug: Angongniuhuang Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of Angongniuhuang Pill
Study: NCT00817609
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of placebo
Study: NCT05388487
Drug: HF1K16 /Arm 45 mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Study: NCT05388487
Drug: HF1K16 /Arm 90 mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Study: NCT05388487
Drug: HF1K16 /Arm 120 mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Study: NCT05388487
Drug: HF1K16 /Arm 160 mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Study: NCT05388487
Drug: HF1K16 /Arm 120 mg or 180 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Study: NCT06500507
Drug: QLS4131 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants confirming to the eligibility criteria will be assigned to 1 of the 9 dose groups (0.06/0.3/1 \~ 600 ug/kg, respectively) based on the sequence of inclusion.
Study: NCT06247748
Drug: Rosuvastatin calcium tablets
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: D8 received a single oral administration of 10 mg of Rosuvastatin calcium tablets in the morning, with a washout period of 168 h,and 10 mg Rosuvastatin calcium tablets orally at 72 h ± 0.5 h (D95) after JY09 administration.
Study: NCT04910620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo only
Study: NCT04910620
Drug: TCI378
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCI378 (Lactobacillus plantarum TCI378)
Study: NCT04910620
Drug: TCI507
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCI507 (Lactobacillus plantarum TCI507)
Study: NCT05994287
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients received ketorolac in a dose of 90 mg mg orally daily.
Study: NCT05994287
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients received celecoxib in a dose of 400 mg orally daily.
Study: NCT05880524
Drug: Isotonic Saline Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive an intravenous dose of Isotonic saline solution twice within within 24±6 hours after symptom onset, administered as a bolus.
Study: NCT00000720
Drug: Globulin, Immune
Normalized name: globulin, immune
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05077969
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg (initial dose), then 200 mg capsule, BID for 5 days
Study: NCT05077969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, QID for 14 days; capsule, BID for 5 days
Study: NCT05620940
Drug: Vivitrol Injectable Product
Normalized name: Vivitrol Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone Long-Acting Injection
Study: NCT05620940
Drug: IVL3004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone Long-Acting Injection
Study: NCT05620940
Drug: IVL4002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone Long-Acting Injection
Study: NCT06643143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05532800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS002:150mg(1mL) Q2W AI, Placebo: 1mL Q2W AI.
Study: NCT06241352
Drug: statin addition to chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy was administered along with 80mg of atorvastatin per day. Atorvastatin was discontinued when CA19-9 levels (with CA19-9 negative patients referenced against CEA or CA-125) rose more than 20% above baseline.
Study: NCT05492045
Drug: Other
Normalized name: others
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of NSCLC.
Study: NCT05214573
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the data who filled a sulfonylurea
Study: NCT05164653
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment, other than Sacubitril Valsartan Sodium Hydrate, for HF
Study: NCT06550128
Drug: AHB-137 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHB-137 injection will be administered subcutaneously.
Study: NCT06550128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously.
Study: NCT06637150
Drug: endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard endocrine therapy
Study: NCT06638905
Drug: Babor Ultimate ECM Repair Serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: The BABOR® Ultimate ECM Repair Serum contains Biogen plant extract, cotton thistle flower, and wakame extract. Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
Study: NCT06638905
Drug: Babor Cure Cream
Normalized name: Cocci-Cure C for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
Study: NCT06645223
Drug: No Interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: no interventions
Study: NCT05949385
Drug: ZX-7101A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral administration of ZX-7101A and Multiple dose of oral of Itraconazole Capsules
Study: NCT04892277
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04938427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat placebo-matching mini-tablets or tablets.
Study: NCT05026801
Drug: Azithromycin plus hydroxychloroquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive active comparator. One group will receive placebo on D1-3 followed by active comparator D4-9, while the other group will receive active comparator D1-6 followed by placebo D7-9.
Study: NCT05031897
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05726968
Drug: Pilocaine 2% (1.5 ml) and 25 ug fentany
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly allocated into the study groups according to the list of random numbers. The study groups will be as follows:~* Group P1 (N 15): patients assigned to this group will receive intrathecal 30 mg (1.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).~* Group P2 (N 15): patient assigned to this group will receive intrathecal 40 mg (2 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml).~* Group P3 (N 15): patient assigned to this group will receive intrathecal 50 mg (2.5 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml).
Study: NCT06554821
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive rosuvastatin (dose 1 or dose 2) orally as a single dose on Day 1 in Period 1 and Day 6 in Period 2.
Study: NCT05548283
Drug: Aminoglycoside
Normalized name: Aminoglycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) aminoglycoside will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
Study: NCT06436781
Drug: Maolactin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dose of 2 capsules containing a total of 500mg/day Maolactin
Study: NCT05103332
Drug: Indapamide
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide administered orally
Study: NCT05103332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by subcutaneous (SC) injection
Study: NCT06418308
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mcg of epinephrine
Study: NCT06418308
Drug: Standardized Spinal Mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized spinal mixture of 10.25 mg hyperbaric bupivacaine, and 0.125 mg morphine.
Study: NCT06220318
Drug: C019199
Approvals — FDA: no, EMA: no, PMDA: no
Description: The C019199 will be taken orally, once a day
Study: NCT05744479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo for 24 weeks
Study: NCT05509127
Drug: Modified universal adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of the modified universal adhesive is done according to manufacturer's instructions using a micro-brush. It is actively rubbed for 20 seconds, gently air-dried for 5 seconds then light cured for 20 seconds.
Study: NCT05509127
Drug: Conventional universal adhesive
Normalized name: STATLOCK UNIVERSAL PLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of the conventional Single Bond Universal adhesive is done using a micro-brush followed by rubbing for 20 seconds, gentle air drying for 5 seconds then light curing for 20 seconds.
Study: NCT06607770
Drug: Karelizumab+Apatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Karelizumab 200mg, q3w, and Apatinib 250mg, qd. every 3 weeks as a treatment cycle.
Study: NCT06625710
Drug: GV1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized peptide from hTERT
Study: NCT06625710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 % Normal Saline
Study: NCT05557708
Drug: 212-Lead Pentixather
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentixather radiolabeled with 212-lead to target malignant cells with the CXCR4 ligand.
Study: NCT05928169
Drug: Topical and systemic drugs
Normalized name: Estradiol and Levonorgestrel Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recruitment and follow-up will be independent on the type of treatment
Study: NCT06173999
Drug: SHR2554/CHOEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2554 with CHOEP
Study: NCT05918029
Drug: Potassium Citrate and Citric Acid Oral Solution
Normalized name: Potassium Citrate and Citric Acid Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral potassium citrate and citric acid
Study: NCT04272034
Drug: INCB099318
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB099318 administered orally in 20 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle.
Study: NCT04987775
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo bid
Study: NCT06571682
Drug: Inhalation anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the inhalation anesthesia group, maintenance sevoflurane anesthesia will be applied after routine induction.
Study: NCT04531579
Drug: Isotonic saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
Study: NCT06252584
Drug: Vaccines, Peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-peptide vaccine cocktail comprising 9 different immunopeptidome-defined mutated and non-mutated AML/ leukemia stem and progenitor cell (LSC)-associated HLA class I and HLA class II peptides. The vaccine cocktail is synthesized and formulated in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen.
Study: NCT06298058
Drug: SIBP-A13 formulation for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIBP-A13: injection; strength: 1, 2, 4, 5, 6 or 8 mg; dose escalation and the first group is 1mg (intravenous infusion). Starting from the lowest dose, when the former does not meet the termination criteria, then start the next dose group study until Maximum Tolerated Dose (MTD). The study adopts a 3+3 dose increasing design. Administration period: divided into single administration and multiple administration. Single dose administration: The participants are administered a single dose on the first day for a total of 21 days of observation, and complete the examinations and evaluations specify in the protocol. If dose-limiting toxicity (DLT) does not occur, the participant enters a multiple dosing period. Multiple administration: administration every 3 weeks.
Study: NCT05195723
Drug: WP1122
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT05195723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT06389123
Drug: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
Study: NCT02465008
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06344247
Drug: simagliptin：Forxiga®️
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide®️ : titrated to the target dose (1 mg qw).
Study: NCT05274477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: no active component
Study: NCT06424002
Drug: artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A therapeutic dose of artemether-lumefantrine (20 mg of artemether and 120 mg of lumefantrine) will be given twice a day for 3 days based on the weight of the child as per treatment guidelines.
Study: NCT06489015
Drug: Recombinant Human Serum Albumin
Normalized name: RECOMBINANT HUMAN SERUM ALBUMIN ORYZA SATIVA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each group receives the investigational drug (recombinant human serum albumin), with the distinction being the variation in dosing.
Study: NCT05995392
Drug: Topical spironolactone ophthalmic solution, 0.005 mg/cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used four times a day in both eyes for 4 weeks.
Study: NCT05995392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used four times a day in both eyes for 4 weeks.
Study: NCT06527677
Drug: ANT3310
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANT3310 will be administered as a single intravenous infusion over 3 hours at a constant rate.
Study: NCT04861337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is infused at a rate same as in the remimazolam group from end of anesthesia induction until 15 minutes before the end of surgery.
Study: NCT05399173
Drug: medical treatment(desmopressin acetate)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will receive medical treatment (desmopressin acetate) per-night dose of 120 g (for 6 weeks) \& advice
Study: NCT06539182
Drug: DZD8586
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose of DZD8586 at 25 mg.
Study: NCT06539182
Drug: DZD8586
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose of DZD8586 at 50 mg.
Study: NCT06539182
Drug: DZD8586
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose of DZD8586 at 75 mg.
Study: NCT06264596
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The epinephrine group will have two 3-L normal saline solution bags prepared for each case with 1 mL of 1:1000 epinephrine in each bag
Study: NCT06565117
Drug: White yu green skin lotion
Normalized name: green ash pollen extract / white ash pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Systemic emollient was applied twice daily for 8 weeks Group B: Continue applying skin lotion twice daily in locally affected skin areas or in areas previously affected by AD for 8 weeks
Study: NCT06195202
Drug: AIs
Normalized name: THAIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with AIs